Molecular Determinants of Cellular Sensitivity to Flavopiridol, and Anti-Cell Signaling Anticancer Agent
Abstract
Flavopiridol is an investigational drug undergoing Phase II clinical trials for the treatment of various solid tumors. This drug has been shown to inhibit of the cyclin-dependent protein kinases, which are essential mediators of the cell division cycle. While this activity is likely to be responsible for its anticancer activity, it is nevertheless unclear how this drug achieves selective toxicity. To address this question, we created a flavopiridol-resistant cell line. The experiments described in this proposal are designed to identify the mechanism(s) responsible for rendering this cell line drug-resistant. Levels of cyclin-dependent protein kinase activity in this resistant cell line will be determined, and compared to those seen in the parental, drug-sensitive cell.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA388574
Entities
People
- Colin R. Campbell
Organizations
- University of Minnesota